A review of heart failure management in the elderly population

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 5, 2009, Pages 233-249

  Cheng, Judy W M ^a,b   Nayar, Monica ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

elderly; geriatrics; heart failure; pharmacotherapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOLAZONE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ANURIA; ARTHRITIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM RETENTION; SYSTOLIC DYSFUNCTION; VISUAL DISORDER; WATER RETENTION;

AGE FACTORS; AGED; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; COMORBIDITY; DRUG INTERACTIONS; DRUG MONITORING; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 71749117327     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.10.001     Document Type: Review

References (75)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 119 (2009) e391-e479
2. Lloyd-Jones D., Adams R., Carnethon M., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119:e182]. Circulation 119 (2009) e21-e181
3. World Health Organization (WHO). Definition of an older or elderly person. http://www.who.int/healthinfo/survey/agerngdemolder/en/index.html Accessed February 22, 2009.
4. Garg R., Yusuf S., and Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [published correction appears in JAMA. 1995;274:462]. JAMA 273 (1995) 1450-1456
5. Rydén L., Armstrong P.W., Cleland J.G., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 21 (2000) 1967-1978
6. Giles T.D., Katz R., Sullivan J.M., et al., Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol. 13 (1989) 1240-1247
7. Granger C.B., McMurray J.J., Yusuf S., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: The CHARM-Alternative trial. Lancet. 362 (2003) 772-776
8. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 345 (2001) 1667-1675
9. McMurray J.J., Ostergren K., Swedberg K., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 362 (2003) 767-771
10. Yusuf S., Pfeffer M.A., Swedberg K., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet. 362 (2003) 777-781
11. Packer M., Bristow M.R., Cohn J.N., et al., US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334 (1996) 1349-1355
12. Packer M., Coats A.J., Fowler M.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344 (2001) 1651-1658
13. Hjalmarson A., Goldstein S., Fagerberg B., et al., Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 283 (2000) 1295-1302
14. Cardiac Insufficiency Bisoprolol Study (CIBIS) Investigators and Committees. A randomized trial of beta-blockade in heart failure. Circulation 90 (1994) 1765-1773
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS- II): A randomised trial. Lancet 353 (1999) 9-13
16. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al., Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carve- dilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet. 362 (2003) 7-13
17. Dulin B.R., Haas S.J., Abraham W.T., and Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol. 95 (2005) 896-898
18. Ghio S., Magrini G., Serio A., et al., SENIORS Investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: Results of the SENIORS echocardiographic sub-study [published correction appears in Eur Heart J. 2006;27:1760]. Eur Heart J. 27 (2006) 562-568
19. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341 (1999) 709-717
20. Pitt B., Remme W., Zannad F., et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271]. N Engl J Med. 348 (2003) 1309-1321
21. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336 (1997) 525-533
22. Adams Jr. K.F., Gheorghiade M., Uretsky B.F., et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 39 (2002) 946-953
23. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
24. Packer M., Gheorghiade M., Young J.B., et al., RADIANCE Study Group. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329 (1993) 1-7
25. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 314 (1986) 1547-1552
26. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325 (1991) 303-310
27. Taylor A.L., Ziesche S., Yancy C., et al., African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears N Engl J Med. 2005;352:1276]. N Engl J Med. 351 (2004) 2049-2057
28. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325 (1991) 293-302
29. Carson P., Ziesche S., Johnson G., Cohn J.N., and Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. J Card Fail. 5 (1999) 178-187
30. Cleland J.G., Tendera M., Adamus J., et al., PEP- CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27 (2006) 2338-2345
31. Massie B.M., Carson P.E., McMurray J.J., et al., I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359 (2008) 2456-2467
32. Doba N., Tomiyama H., and Nakayama T. Drugs, heart failure and quality of life: What are we achieving? What should we be trying to achieve?. Drugs Aging. 14 (1999) 153-163
33. Komajda M., Hanon O., Hochadel M., et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 30 (2009) 478-486
34. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of myocardial infarction: Systemic overview of individual data from 100,000 patients in randomized trials. Circulation. 97 (1998) 2202-2212
35. Murray M.D., Haag K.M., Black P.K., et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 17 (1997) 98-106
36. Robinson T., Gariballa S., Fancourt G., et al. The acute effects of a single dopamine infusion in elderly patients with congestive cardiac failure. Br J Clin Pharmacol. 37 (1994) 261-263
37. Velagaleti R., and Vasan R.S. Heart failure in the twenty-first century: Is it a coronary artery disease or hypertension problem?. Cardiol Clin. 25 (2007) 487-495
38. Velagaleti R., and Vasan R.S. Heart failure in the twenty-first century: Is it a coronary artery disease or hypertension problem?. Cardiol Clin. 25 (2007) v
39. Kawaguchi M., Hay I., Fetics B., and Kass D.A. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation. 107 (2003) 714-720
40. Chae C.U., Albert C.M., Glynn R.J., et al. Mild renal insufficiency and risk of congestive heart failure in men and women ≥70 years of age. Am J Cardiol. 92 (2003) 682-686
41. Swedberg K., Cleland J., Dargie H., et al., European Society of Cardiology, Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). Eur Heart J. 26 (2005) 1115-1140
42. Maisel A.S., Krishnaswamy P., Nowak R.M., et al., Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347 (2002) 161-167
43. Braunstein J.B., Anderson G.F., Gerstenblith G., et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 42 (2003) 1226-1233
44. Rich M.W. Office management of heart failure in the elderly. Am J Med. 118 (2005) 342-348
45. McDonald K. Diastolic heart failure in the elderly: Underlying mechanisms and clinical relevance. Int J Cardiol. 125 (2008) 197-202
46. Krumholz H.M., Chen Y.T., Vaccarino V., et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 85 (2000) 1110-1113
47. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol. 13 (2002) 1928-1936
48. Kosiborod M., Smith G.L., Radford M.J., et al. The prognostic importance of anemia in patients with heart failure. Am J Med. 114 (2003) 112-119
49. Mascarenhas J., Lourenço P., Lopes R., et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 155 (2008) 521-525
50. Vaccarino V., Kasl S.V., Abramson J., and Krumholz H.M. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 38 (2001) 199-205
51. Page J., and Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med. 160 (2000) 777-784
52. Vogels R.L., Scheltens P., Schroeder-Tanka J.M., and Weinstein H.C. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail. 9 (2007) 440-449
53. Persson M.D., Brismar K.E., Katzarski K.S., et al. Nutritional status using mini nutritional assessment and subjective global assessment predict mortality in geriatric patients. J Am Geriatr Soc. 50 (2002) 1996-2002
54. Zuckerman J.D. Hip fracture. N Engl J Med. 334 (1996) 1519-1525
55. Litaker J.R., and Chou J.Y. Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: A review of the literature. Clin Ther. 25 (2003) 1918-1935
56. 2009 Physicians' Desk Reference (PDR). 63rd ed. (2009), Thomson Reuters, Chicago, Ill
57. Packer M., Lee W.H., Medina N., et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 106 (1987) 346-354
58. Woo K.S., and Nicholls M.G. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 40 (1995) 141-144
59. Israili Z.H., and Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 117 (1992) 234-242
60. Cicardi M., Zingale L.C., Bergamaschini L., and Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: Outcome after switching to a different treatment. Arch Intern Med. 164 (2004) 910-913
61. Warner K.K., Visconti J.A., and Tschampel M.M. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 34 (2000) 526-528
62. Kramer J.M., Curtis L.H., Dupree C.S., et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med. 168 (2008) 2422-2428 discussion
63. Kramer J.M., Curtis L.H., Dupree C.S., et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med. 168 (2008) 2428-2432
64. Brater D.C. Diuretic therapy. N Engl J Med. 339 (1998) 387-395
65. Cody R.J., Kubo S.H., and Pickworth K.K. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 154 (1994) 1905-1914
66. Cody R.J., Franklin K.W., and Laragh J.H. Postural hypotension during tilt with chronic captopril and diuretic therapy for severe congestive heart failure. Am Heart J. 103 (1982) 480-484
67. Massie B., Kramer B., and Haughom F. Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation. 63 (1981) 658-664
68. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 351 (2004) 543-551
69. Abraham W.T., Greenberg B.H., and Yancy C.W. Pharmacologic therapies across the continuum of left ventricular dysfunction. Am J Cardiol. 102 (2008) 21G-28G
70. Jolobe O.M. Evaluation of renal function in elderly heart failure patients on ACE inhibitors. Postgrad Med J. 75 (1999) 275-277
71. Metoprolol. Drugdex system. http://www.thomsonhc.com.ezproxy.mcphs.edu/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/C562DE/DUPLICATIONSHIELDSYNC/858FEC/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/0251/ContentSetId/31/SearchTerm/metoprolol%20/SearchOption/BeginWith Accessed October 7, 2009
72. Sin D.D., and McAlister F.A. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 113 (2002) 650-656
73. Masoudi F.A., Havranek E.P., Smith G., et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. 41 (2003) 217-223
74. Tehrani F., Phan A., Chien C.V., et al. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol. 103 (2009) 829-833
75. Allen L.A., Yager J.E., Funk M.J., et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 299 (2008) 2533-2542